The Phase 1 portion of the seviteronel study has completed and a once-daily dose was selected for advancement into Phase 2 development. William Moore, Ph.D., Innocrin’s Chief Executive
Orphan drug designation provides certain exclusivity benefits, tax credits for certain research, longer exclusivity and a waiver of the New Drug Application user fee. The designation is made
An independent data monitoring committee observed that patients taking the drug in the trial were at a possible increased risk for death and other severe adverse events as
Sunshine will market and sell this new pharmaceutical product under its own label. Sunshine is currently in the process of securing a Drug Identification Number ("DIN") for its
Additional new investors include Aju IB Investment, Cowen Private Investments, Franklin Templeton Investments and Rock Springs Capital. All existing investors participated in the financing: Eshelman Ventures, Hatteras Venture
ONSOLIS is an opioid agonist indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are
The compound is an oral and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1), which is being developed by H3 Biomedicine as an anticancer therapeutic
The study is entitled "A Double-Blind Placebo-Controlled Phase IIb Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults
To develop drugs that would prevent viruses from causing infections, researchers need to know the genetic mechanisms that viruses use to infect healthy cells. Those mechanisms become the
JHL will use the KUBio manufacturing solution delivered by GE Healthcare to manufacture biosimilars1 and monoclonal antibodies (mAbs) for late-stage clinical trials and commercial supply. The facility will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.